Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/5927
Title: | CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia | Authors: | Balıbey, Hakan Başoğlu, Cengiz Lundgren, Stefan Babaoğlu, Melih Ö. Yaşar, Ümit Herken, Hasan Rane, Anders Bozkurt, Atilla Çetin, Mesut |
Keywords: | Clozapine CYP1A2 Schizophrenia Smoking clozapine cytochrome P450 1A2 cytochrome P450 1A2 1F unclassified drug adult article biochemistry Brief Psychiatric Rating Scale cigarette smoking drug dose increase drug megadose female follow up gene frequency genetic polymorphism genotype human major clinical study male psychologic assessment psychologic test psychosis retrospective study Scale for the Assessment of Negative Symptom Scale for the Assessment of Positive Symptom schizophrenia single nucleotide polymorphism treatment duration treatment response wild type |
Abstract: | Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or occurrence of side effects of antipsychotic drugs. Aim: We studied the association of response to clozapine treatment in schizophrenic patients in relation to polymorphisms in the CYP1A2 gene. Methods: The degree of psychosis of the patients (n=55) was assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS) and routine biochemistry. The patients were monitored for 18 weeks and the scales were applied before starting the treatment and at the end of the follow up period. Clozapine was used at doses of 200 to 600 mg/day. A positive response was defined as a 20% decrease in pre-and posttreatment scores of one of the BPRS, SANS, or SAPS scores. In addition, 45 patients, who were already on clozapine treatment, were assessed retrospectively. Results: As assessed at the 18th week after start of therapy, lack of response to clozapine treatment was 2.4 fold higher in the patients carrying the CYP1A2*1F*1F genotype (p=0.02) compared to patients carrying at least one wild type allele (i.e. *1/*1 or *1/*1F). Smoking decreased the response rate by about 15% (p=0.014). Conclusion: The results of our study suggest that the CYP1A2*1F/*1F genotype may be a risk factor for lack of response to clozapine treatment in psychotic patients, especially in cigarette smokers. | URI: | https://hdl.handle.net/11499/5927 https://doi.org/10.5455/bcp.20110622071701 |
ISSN: | 1017-7833 |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
f78c31f0-aa7a-4003-acf1-d39625191b7d.pdf | 277.96 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
22
checked on Aug 17, 2024
WEB OF SCIENCETM
Citations
19
checked on Aug 9, 2024
Page view(s)
52
checked on Aug 24, 2024
Download(s)
16
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.